高级检索
当前位置: 首页 > 详情页

Nocardia rubra cell wall skeleton regulates tumour-associated macrophage polarization by reprogramming M2 macrophages into M1 macrophages via STAT1/STAT6 pathways

文献详情

资源类型:
WOS体系:
Pubmed体系:

收录情况: ◇ SCIE

机构: [1]Hebei Med Univ, Dept Histol & Embryol, 361 Zhongshan East Rd, Shijiazhuang 050017, Peoples R China [2]Liaoning Tianan Biopharmaceut Co Ltd, New Drug R&D Ctr, Benxi, Peoples R China [3]Hebei Med Univ, Hosp 1, Dept Gynaecol, Shijiazhuang, Peoples R China [4]Hebei Med Univ, Hosp 4, Dept Gynaecol, Shijiazhuang, Peoples R China
出处:
ISSN:

关键词: macrophage polarization Nocardia rubra cell wall skeleton tumour-associated macrophage

摘要:
Targeted therapy with tumour-associated macrophages (TAMs) has emerged as a new paradigm for immunotherapy of cervical cancer. Nocardia rubra cell wall skeleton (Nr-CWS) for external use is an immunotherapeutic agent. In this study, we aimed to explore the effects of Nr-CWS on TAMs and the potential mechanisms. Cervical tissue samples were collected before and after Nr-CWS treatment from patients with high-risk HPV infection and cervical intraepithelial neoplasia (CIN). The effect of Nr-CWS on macrophages in vivo was examined by immunohistochemistry and double-labeling immunofluorescence histochemistry. In vitro experiments were performed using a TAM model established by THP-1 cells under Nr-CWS treatment. We found that Nr-CWS treatment significantly reduced the numbers of total macrophages and M2 macrophages, increased the proportion of M1 macrophages and decreased the proportion of M2 macrophages in cervical tissues. After Nr-CWS treatment in vitro, the expression levels of the M1 macrophage markers were increased, while the expression levels of the M2 macrophage markers were decreased. Nr-CWS treatment also activated STAT1 pathways but inhibited STAT6 pathways. These results indicated that Nr-CWS may improve local immune response and reverse immunosuppression by regulating the M2 to M1 polarization of TAMs via STAT1/STAT6 pathways.

基金:

基金编号: 2022YFC2704400 H2020206243 20220972

语种:
被引次数:
WOS:
PubmedID:
中科院分区:
出版当年[2023]版:
大类 | 4 区 医学
小类 | 4 区 免疫学
最新[2025]版:
大类 | 4 区 医学
小类 | 4 区 免疫学
JCR分区:
出版当年[2023]版:
Q2 IMMUNOLOGY
最新[2024]版:
Q4 IMMUNOLOGY

影响因子: 最新[2024版] 最新五年平均 出版当年[2023版] 出版当年五年平均 出版前一年[2022版] 出版后一年[2024版]

第一作者:
第一作者机构: [1]Hebei Med Univ, Dept Histol & Embryol, 361 Zhongshan East Rd, Shijiazhuang 050017, Peoples R China
共同第一作者:
通讯作者:
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:42329 今日访问量:0 总访问量:1365 更新日期:2025-08-01 建议使用谷歌、火狐浏览器 常见问题

技术支持:重庆聚合科技有限公司 地址:河北省石家庄市健康路12号